Geographical Differences in the Management and Outcomes of PatientsWith Advanced Urothelial Carcinoma Treated With Pembrolizumab AfterProgression on Platinum-Based Chemotherapy: Results From ARON-2Study
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients withmetastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell RenalCell Carcinoma: Results from the ARON-1 Study
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
mRNA expression, tumor heterogeneity, and response to therapy inpatients with advanced renal cell carcinoma treated with immune-basedcombinations (ARON-1α)
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study